1. |
Options for infertility treatment reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Treatments for IBD reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Ciprofloxacin/hydrocortisone warranted for otitis externa in France |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
QOL an important endpoint among patients treated for NSCLC |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 5-5
Cameron Johnston,
Preview
|
|
摘要:
Differences in median survival time in patients treated for advanced non-small-cell lung cancer (NSCLC) have been modest and statistically insignificant, regardless of the platinum-based drug regimen used. Therefore, quality of life (QOL) measurements have become important surrogate endpoints for evaluating a patient's response to a particular drug regimen. In a study presented at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Orlando, US; May 2002], docetaxel/cisplatin appeared to provide greater improvements in QOL than either docetaxel/carboplatin or vinorelbine/cisplatin. The latter regimen is currently the generally accepted standard treatment for patients with this form of lung cancer.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Infliximab improves QOL in active and fistulising Crohn's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Novel strategies for multiple sclerosis?LIF: improves disease severity in MS animal model |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Duloxetine provides effective treatment for depression |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 9-10
Ngaire Polwart,
Preview
|
|
摘要:
Duloxetine ['Cymbalta'], a serotonin/norepinephrine inhibitor (SNRI), is well tolerated and effective in the treatment of depression, according to studies presented at the 155th Annual Meeting of the American Psychiatric Association (APA) [Philadelphia, US; May 2002].*Results from several phase III studies demonstrated the superiority of duloxetine, administered once or twice daily, over placebo. Furthermore, duloxetine proved more effective than the selective serotonin reuptake inhibitor (SSRI), paroxetine, in one of these studies. Data from pooled studies demonstrated that duloxetine has a favourable tolerability profile, with minimal effects on bodyweight, cardiovascular abnormalities and sexual function.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Paediatric otitis media: who to treat with antibacterials? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Simvastatin reduces cardiovascular risk |
|
Inpharma Weekly,
Volume &NA;,
Issue 1346,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|